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Abstract
Background: Bone remodeling relies on the tightly regulated interplay between bone forming osteoblasts and bone
digesting osteoclasts. Several studies have now described the molecular mechanisms by which osteoblasts control
osteoclastogenesis and bone degradation. It is currently unclear whether osteoclasts can influence bone rebuilding.
Methodology/Principal Findings: Using in vitro cell systems, we show here that mature osteoclasts, but not their
precursors, secrete chemotactic factors recognized by both mature osteoblasts and their precursors. Several growth factors
whose expression is upregulated during osteoclastogenesis were identified by DNA microarrays as candidates mediating
osteoblast chemotaxis. Our subsequent functional analyses demonstrate that mature osteoclasts, whose platelet-derived
growth factor bb (PDGF-bb) expression is reduced by siRNAs, exhibit a reduced capability of attracting osteoblasts.
Conversely, osteoblasts whose platelet-derived growth factor receptor b (PDGFR-b) expression is reduced by siRNAs exhibit
a lower capability of responding to chemotactic factors secreted by osteoclasts.
Conclusions/Significance:We conclude that, in vitro mature osteoclasts control osteoblast chemotaxis via PDGF-bb/PDGFR-
b signaling. This may provide one key mechanism by which osteoclasts control bone formation in vivo.
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Introduction
Bones undergo remodeling to maintain the mass, the shape and
the physical properties of the skeleton. Two major cell types, the
bone-forming osteoblasts and the bone-resorbing osteoclasts
contribute to this process, which occurs continuously throughout
life. The balance between bone formation and degradation is
normally tightly controlled but it becomes deregulated, shifting
towards more degradation under pathological conditions or during
aging, thereby leading to osteoporosis [1,2]. This tight balance
implies the existence of mechanisms coordinating the differenti-
ation of osteoblasts and osteoclasts as well as their migration to
locations where they function.
The mechanisms by which osteoblasts control the differentiation
of hematopoietic osteoclast precursors towards mature multinucle-
ated cells, i.e. osteoclastogenesis, are now established [3]. Osteoblasts
and stromal cells control bone degradation by expressing the
Macrophage-Colony Stimulating Factor (M-CSF) required for the
proliferation of osteoclast precursors and the Receptor for Activation
of NF-kB Ligand (RANKL), a TNF family member triggering their
differentiation [1,3–7]. The mechanisms controlling the differenti-
ation of mesenchymal stromal cells (MSCs) towards osteoblasts, i.e
osteoblastogenesis, are less understood. During the past years, several
signaling molecules have been implicated in bone development and
osteogenesis [8]. These include fibroblast growth factors, parathyroid
hormone complexes [9], bone morphogenetic proteins (BMPs) [10],
Canonical Wnt [11–14], Indian hedgehog [15] and epidermal
growth factor [16]. However, the cell types producing these factors
have remained elusive. There is evidence however, that osteoclasts
can control osteoblast function. Ephrin B2 expressed by osteoclasts
and its Ephrin B4 receptor expressed by osteoblasts allow
bidirectional signaling [17]. Signaling through Ephrin B4 into
osteoblasts enhances osteogenic differentiation whereas signaling
through Ephrin B2 into osteoclast precursors suppresses osteoclast
differentiation. It has also been reported that the v-ATPase V0
subunit D2 is not only involved in osteoclast fusion but also regulates
the secretion by osteoclasts of still unidentified factors that inhibit the
differentiation of osteoblast precursors into mature cells [18].
During development, osteoblasts must colonize the cartilage
that will be replaced by bone. During adulthood, bone remodeling
and repair require the migration of osteoblasts to bone areas that
need to be rebuilt. This latter process also requires the
mobilization of their progenitors residing together with MSCs
into niches of the bone marrow [19,20]. A plethora of growth
factors used as recombinant proteins, in particular BMPs, platelet-
derived growth factor (PDGF), vascular endothelial growth factor
(VEGF) and leukemia inhibitory factor (LIF), have been shown to
exhibit in vitro chemotactic activities towards various cell types
including osteoblasts and their progenitors [21,22]. However, it is
still unclear which cell types in the bone matrix secrete the factors
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able to attract bone rebuilding cells, which growth factors can
function in this context and how the migration of bone rebuilding
cells is coordinated with bone digestion.
We tested here the hypothesis that osteoclasts can control
osteoblast chemotaxis. Using in vitro cell systems of osteoclastogen-
esis and osteoblasto-genesis, we show that mature osteoclasts
secrete PDGF-bb, which is recognized by PDGF receptor b
(PDGFR-b) on the surface of osteoblasts and regulates osteoblast
chemotaxis. Thus, this in vitro study provides the first molecular
basis for further investigating the importance of the PDGF-bb/
PDGFR-b signaling pathway in bone remodeling in vivo.
Results
In order to test whether osteoclasts can signal to osteoblasts, we
used in vitro cell systems of osteoclastogenesis or osteoblastogenesis.
First, we used the mouse monocyte/macrophage-like Raw264.7
cells, which differentiate in vitro towards mature osteoclasts upon
stimulation with the osteoclastogenic cytokine RANKL. Raw264.7
cell-derived osteoclasts conform to conventional assays for
osteoclast function as primary osteoclasts isolated from bones.
Primary osteoclast precursors from mouse bone marrow and
derived osteoclasts were also used. Second, we used the mouse pre-
osteoblastic MC3T3-E1 cells that differentiate in vitro towards
mature osteoblasts upon stimulation with chemical cocktails
containing dexamethasone, ascorbic acid and b-glycerophosphate.
The MC3T3-E1-derived osteoblasts express the typical markers of
osteoblasts isolated from bones.
Osteoclasts secrete factors attracting osteoblasts
We first tested whether the conditioned medium of Raw264.7 cells
or Raw264.7-derived osteoclasts could attract pre-osteoblastic
MC3T3-E1 cells or MC3T3-E1-cell derived osteoblasts. For this,
we used the Boyden chamber assay to measure chemotaxis.
Figure 1. Chemotaxis response of osteoblasts and precursors to factors secreted by osteoclasts. Raw264.7 cells were grown in the
presence or absence of RANKL. Conditioned media were collected every day. The chemotactic activity of the corresponding conditioned media
towards pre-osteoblastic MC3T3-E1 cells and derived osteoblasts was measured as described under materials and methods. Migration Index of mouse
pre-osteoblastic MC3T3-E1 cells (A) and derived osteoblasts (diff MC3T3-E1) (C) in response to conditioned media of Raw264,7 cells (%) and derived
osteoclasts (N). Chemotaxis of pre-osteoblastic MC3T3-E1 cells (B) and derived osteoblasts (D) by conditioned media of primary osteoclasts and their
precursors. For comparison, the chemotactic activity of conditioned media from Raw264, 7 cells and derived osteoclasts collected after 2 and 4 days
of differentiation are shown. Shown are mean values6S.D. of four independent experiments performed in triplicates. P values from ANOVA tests
equal or less than 0.05 were considered significant and are marked with an asterisk (*).
doi:10.1371/journal.pone.0003537.g001
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Figure 1A shows that the chemotactic activity of Raw264.7 cells
towards MC3T3-E1 cells was rather low. However, their chemo-
tactic activity increased with time when they were differentiated
towards osteoclasts upon stimulation with RANKL. After 4 days of
RANKL-induced differentiation, the conditioned medium of Raw-
derived osteoclasts exhibited a clear chemotactic activity towards
MC3T3-E1 cells (Fig. 1A). This activity was also observed with the
conditioned medium of osteoclasts derived from bone marrow
progenitors stimulated by M-CSF and RANKL (Fig. 1B). The
conditioned medium of Raw264.7-derived osteoclasts also exhibited
a chemotactic activity towards MC3T3-E1-derived osteoblasts,
although to a lower extent (Fig. 1C). The chemotatic index of
mature osteoclast conditioned media was two fold higher towards
pre-osteoblastic MC3T3-E1 cells when compared to MC3T3-E1
cell-derived osteoblasts. Similar results were obtained with the
conditioned media of primary osteoclasts derived from bone marrow
progenitors (Fig. 1D). We conclude from these results that, during
their differentiation osteoclasts derived from Raw264.7 cells or
primary bone marrow progenitors acquire the capability of secreting
chemotactic factors able to attract osteoblast precursors and, to a
lower extent mature osteoblasts.
Identification of putative chemotactic factors
The results described above strongly suggest that the genes
encoding chemotactic factors secreted by mature osteoclasts are
upregulated during osteoclastogenesis. To identify candidates, we
took advantage of our previous DNA microarray analyses
comparing the gene expression patterns of Raw264.7 cells and
derived osteoclasts [23]. We identified eighteen genes upregulated
during osteoclastogenesis, encoding secreted proteins, in particular
PDGF-bb, vascular endothelial growth factor c (VEGFc), leukemia
inhibitory factor (LIF) and cytokines such as the chemokine (C-C
motif) ligand 9 (CCL9), interleukin-1 receptor antagonist (IL-1ra)
and Twisted gastrulation protein 1 (Twgs1). Quantitative RT-PCR
performed on Raw264. 7 cells and derived osteoclasts shows that,
indeed the expression of PDGF-bb, VEGFc, LIF and IL-1ra was
substantially upregulated during osteoclastogenesis (a 13, 36, 73 and
25 fold increase, respectively) whereas that of CCL9 and Twgs 1 was
upregulated only 2–4 fold (Table 1). Similar results were obtained for
osteoclasts derived from primary osteoclast progenitors from bone
marrow, in which PDGF-bb and LIF expression were even more
strongly upregulated (a 190 and 90 fold increase respectively)
(Table 1). Figure 2 shows that the expression of PDGF-bb, LIF and
IL-1ra increased regularly during the RANKL-induced differenti-
ation of Raw264.7 cells whereas that of VEGFc was maximal after
two days of differentiation and remained constant.
PDGF-bb secreted by osteoclasts mediates osteoblast
chemotaxis
To identify the chemotatic factor(s) secreted by mature osteoclasts,
we used a siRNA-based strategy. Raw264.7-derived osteoclasts were
first electroporated in the presence of siRNA probes and then
maintained in culture. After two days, the silencing efficiencies were
determined by quantitative RT-PCR and the conditioned media of
siRNA-treated osteoclasts were tested for their chemotactic activity.
As shown in figure 3, an efficient siRNA-mediated depletion of
PDGF-bb, VEGFc or LIF (<80%) could be achieved in Raw-derived
osteoclasts. A reduction in PDGF-bb expression in Raw-derived
osteoclasts resulted in a <50% reduction in the ability of their
conditioned medium to attract pre-osteoblastic MC3T3-E1 cells at
every concentration tested. The residual chemotactic activity of pre-
osteoblastic MC3T3-E1 cells by conditioned media of siRNA-treated
osteoclasts most likely reflects the presence of low amounts of PDGF-
bb still secreted by these cells. In addition, this loss of chemotactic
activity after PDGF-bb knockdown could be rescued by the addition
of recombinant PDGF-bb, reaching the same chemotactic activity of
conditioned media of non-siRNA-treated osteoclasts (Fig. 3B). In
contrast, a 80% reduction in VEGFc or LIF expression remained
without any effect on chemotaxis of MC3T3-E1 cells (Fig. 3C–F).
Because recombinant CCL9, IL1ra and Twgs1 did not modify the
chemotactic activity of MC3T3-E1 cells (data not shown), they were
not further considered. We conclude from these results that PDGF-
bb secreted by Raw264.7-derived osteoclasts acts as a potent
chemotatic agent towards preosteoblastic MC3T3-E1 cells.
PDGFR-b on the surface of osteoblasts binds PDGF-bb
secreted by osteoclasts
PDGF-bb binds either to PDGFR-b or PDGFR-a homodimers
or to PDGFR-a/b heterodimers [24]. PDGFR-a and PDGFR-b
mRNAs could be detected in pre-osteoblastic MC3T3-E1 cells,
suggesting that these receptors are expressed on their cell surface.
Using quantitative RT-PCR, we determined their expression
levels during osteoblastogenesis. Table 2 shows that the expression
level of both PDGFR-a and PDGFR-b decreased substantially
when pre-osteoblastic MC3T3-E1 cells were differentiated to-
wards osteoblasts upon induction with chemical cocktails (a<80%
reduction within 8 days of differentiation). For comparison, we
also followed variations in the expression of VEGFR-3, the main
VEGF receptor expressed in pre-osteoblastic MC3T3-E1 cells. Its
expression also decreased during MC3T3-E1 cell differentiation
(Table 2) as that of the LIF receptor (not shown).
Figure 2. Gene expression levels during osteoclastogenesis.
Shown are the expression levels of (&) VEGFc, ($) LIF, (¤) IL1ra, (m)
PDGF-bb, (+) CCL9 and (6) Twgs1 during the RANKL-induced
differentiation of Raw264,7 cells. Quantitative RT-PCR analyses were
performed as described under materials and methods. Data are
expressed in variations of DCt.
doi:10.1371/journal.pone.0003537.g002
Table 1. Growth factors levels during osteoclastogenesis.
Gene Changes in mRNA amounts (folds)
Raw264.7 derived osteoclast Primary osteoclasts
PDGF-bb 13 194
VEGFc 36 6.5
LIF 73 90
IL1ra 25 6
CCL9 4 15
Twgs protein 1 2 2
Raw 264.7 cells and primary osteoclast precursors from bone marrow were
differentiated towards osteoclasts with RANKL as indicated under materials and
methods. After 6 days, changes in gene expression were detected by
quantitative RT-PCR as indicated under materials and methods and normalized
according to GAPDH expression.
doi:10.1371/journal.pone.0003537.t001
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To identify the PDGFR that binds PDGF-bb secreted by
Raw264.7-derived osteoclasts, we also followed a siRNA-based
strategy. Pre-osteoblastic MC3T3-E1 cells or derived osteoblasts
were treated with siRNAs. After 2–3 days, the knockdown
efficiencies were determined by quantitative RT-PCR and the
treated cells were tested for their ability to be attracted by the
conditioned media of Raw264.7 cells or derived osteoclasts.
Figure 4 shows that the knockdown of PDGFR-b in pre-
osteoblastic MC3T3-E1 cells, leading to a <90% reduction in
its expression without affecting PDGFR-a expression, resulted in a
loss of their attraction by conditioned media from Raw264.7-
derived osteoclasts. In contrast, the knockdown of PDGFR-a in
pre-osteoblastic MC3T3-E1 cells, leading to a <90% reduction in
its expression without affecting PDGFR-b expression, did not
affect their attraction by conditioned media from Raw264.7-
derived osteoclasts (Fig. 4C & 4D). Similar results were obtained
when PDGFR-a or b expression were reduced in MC3T3-E1-
derived osteoblasts (Fig. 4 E–H). Furthermore, pre-osteoblastic
MC3T3-E1 cells and derived osteoblasts with reduced PDGFR-b
expression were unable to respond to recombinant PDGF-bb,
Figure 3. PDGF-bb secreted by osteoclasts triggers osteoblast chemotaxis. Genes encoding PDGF-bb, VEGFc, LIF were silenced in Raw264,7
cell-derived osteoclasts as described under materials and methods. Conditioned media of treated osteoclasts were collected and different dilutions
were tested for their chemotactic activity towards pre-osteoblastic MC3T3 cells. Knockdown efficiencies of PDGF-bb (A), VEGFc (C) and LIF (E) in
Raw264,7 cell-derived osteoclasts were determined by quantitative RT-PCR. The knockdown efficiencies were 74%, 71% and 70% respectively
(p,0,00001, ANOVA). Chemoattraction of pre-osteoblastic MC3T3 cells by different dilutions of conditioned media of Raw264,7 cells (N) or Raw264,7
cell-derived osteoclasts (%) in which the expression of PDGF-bb (B), VEGFc (D) and LIF (F) were silenced (p,0,0001, ANOVA). (& in B) Rescue of
PDGF-bb knockdown in osteoclasts: conditioned media of siRNA-treated osteoclasts were supplemented with 10 ng/ml recombinant human PDGF-
bb. Data points represent the average of 5 experiments.
doi:10.1371/journal.pone.0003537.g003
Chemotaxis of Osteoblasts
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thereby providing additional support to the specificity of these
interactions (Figure S1). We conclude from these results that
PDGFR-b is the receptor isoform, which binds PDGF-bb at the
cell surface of pre-osteoblastic MC3T3-E1 cells and derived
osteoblasts.
Discussion
Our study shows that osteoclast precursors up-regulate the
expression of several growth factors during osteoclastogenesis and
that PDGF-bb is the only secreted growth factor triggering in vitro
the chemotaxis of pre-osteoblastic cells and, to a lower extent that
of the corresponding derived osteoblasts. This lower reactivity of
osteoblasts is likely due to a lower expression of PDGFR-b, the
unique PDGFR isoform that binds PDGF-bb and triggers their
chemotaxis. Thus, PDGF-bb/PDGFR-b signaling controls the
chemo-attraction of osteoblasts by osteoclasts in vitro.
Chemotaxis and cell migration are key biological events
necessary for tissue formation and remodeling. Thus, a continuous
supply of osteoblastic cells is required to build the bone tissue at
specific sites during development and for bone remodeling and
fracture healing during adulthood. Our study demonstrates that
mature osteoclasts derived from Raw264.7 cells and primary
progenitors isolated from the bone marrow secrete factors able to
induce the chemotactic response of both preosteoblastic MC3T3-
E1 cells and derived osteoblasts in vitro. This chemotactic activity is
clearly dependent upon the differentiation state of osteoclasts since
osteoclast precursors fail to produce strong chemotactic responses.
Therefore, the genes encoding these chemokines must be strongly
upregulated during the RANKL-dependent differentiation of
osteoclast precursors. DNA microarrays comparing gene expres-
sion between mature osteoclasts and their precursors identified a
group of several genes encoding secreted proteins that are
upregulated during osoteoclastogenesis. Similar results were
obtained using two different systems of osteoclastogenesis, either
mouse Raw264.7 cells [23 and this study] or primary osteoclast
progenitors from mouse bone marrow, and were confirmed by
quantitative RT-PCR analyses. Similar results were also obtained
with human systems of osteoclastogenesis (A. Gallois and P. Jurdic,
unpublished observations). Some of these genes encode known
growth factors, in particular PDGF-bb, VEGFc and LIF. A role
for PDGF-bb in bone formation has been postulated since
recombinant PDGF-bb, as other PDGF isoforms or BMP-2 and
BMP-4 isoforms, has been shown to be a powerful chemoat-
tractant for mesenchymal stromal cells and osteoblasts in vitro [21].
It has been proposed that LIF could modulate the chemotactic
activity of PDGF [25]. However, we found that the pre-treatment
of osteoblasts or osteoclasts with LIF did not modify the
chemotactic response of osteoblasts towards PDGF-bb in vitro
(unpublished observation). Other studies have indicated a critical
role for VEGF during the process of endochondral ossification, in
particular in coupling cartilage resorption with bone formation
[26]. VEGFa has been shown to exhibit in vitro chemotactic
activities towards primary osteoblasts [22]. Thus, our results
confirm previous findings showing that recombinant PDGF-bb
can attract osteoblasts in vitro and also extend these findings by
identifying the mature osteoclasts as a source of this growth factor.
In contrast, it appears that VEGFc secreted by osteoclasts does not
exhibit chemotactic activity towards osteoblasts or their precur-
sors. VEGFc secreted by osteoclasts was recently shown to
function as an autocrine factor regulating osteoclast activity [27].
It remains possible that the other secreted cytokines, as well as
VEGFc, influence the behavior of the other cell types involved in
bone metabolism, a hypothesis, which remains to be tested.
PDGF-bb, as well as other PDGF isoforms, binds with similar
affinities to PDGF receptors consisting of either a, b homodimers
or a/b heterodimers [24]. It has been unclear, which PDGFR
isoform triggers the signaling cascade leading to the chemotaxis of
osteoblasts or their precursors. This issue has been addressed using
anti-PDGFR-a or PDGFR-b blocking antibodies whose specificity
has remained controversial [21]. The inactivation of PDGF-bb or
PDGFR-b genes results in severe cardiovascular, renal, placental,
and hematologic disorders and is therefore embryonic lethal,
rendering phenotypic analyses difficult [28,29,24]. Our study
clearly identifies PDGFR-b at the surface of pre-osteoblastic
MC3T3-E1 cells and derived osteoblasts as the receptor binding
osteoclastic PDGF-bb, thereby triggering their chemotaxis in vitro.
The knockdown of PDGFR-b in osteoblasts or that of PDGF-bb in
mature osteoclasts led to the same phenotype i.e. a loss of
migration of osteoblasts. In contrast, the knockdown of PDGFR-a
remained without any effect on migration. Thus, our in vitro study
strongly suggests that PDGF-bb/PDGFR-b signaling is critical for
bone remodeling and/or fracture healing in vivo [30]. Therefore,
our study could provide a molecular basis for investigating the
importance of this signaling pathway in the context of bone
remodeling. It is currently unknown how PDGFR-b signaling can
trigger the re-organization of actin dynamics required for cell
movement of osteoblasts and their precursors. In mesenchymal
stromal cells, Rho GTPases have been implicated in this process
[30]. In other cell types, the PI-3 kinase and the Rac GTPase have
been implicated in actin remodeling triggered by PDGFR-b
signaling [31], a process in which the Garb1scaffolding/docking
protein and Grb2 have also been involved [32] as well as Nck and
p130Cas [33]. Whereas this aspect needs to be addressed in more
details, one can anticipate that some components of this signaling
cascade are downregulated or differently regulated during
osteoblastogenesesis.
An interesting paradigm arising from our in vitro study is that the
production of PDGF-bb increases during osteoclastogenesis while
the expression of PDGFR-b decreases during osteoblastogenesis.
Mesenchymal stromal cells and osteoblast progenitors are
maintained into niches of the bone marrow [20], where they also
contribute to maintain hematopoietic stem cells [34]. Bone
remodeling requires the mobilization and the migration of
osteoblast progenitors to locations where bone needs to be rebuilt.
Beside its chemotactic activity, PDGF-bb is also believed to act in
vitro as an inhibitory factor of osteoblastogenesis [35]. Our own
unpublished observations would support this contention. Thus, it
Table 2. Growth factor receptor expression levels during
osteoblastogenesis.
Differentiation mRNA expression levels (%)
PDGFR-b PDGFR-a VEGFR-3
Day 0 100 100 100
Day 2 35,7 50 50
Day 4 26.3 27.8 50
Day 6 11.2 20 47.6
Day 8 11.7 16.1 33.4
Differentiation of MC3T3-E1 cells to osteoblasts was induced with
dexamethasone, ascorbic acid and b-glycerophosphate during the indicated
period of time. Changes in gene expression levels were detected by
quantitative RT-PCR as indicated under materials and methods and normalized
according to GAPDH expression.
doi:10.1371/journal.pone.0003537.t002
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could be expected that inhibition of PDGFR-b signaling in
osteoblast progenitors would promote their differentiation towards
osteoblasts. This latter issue has been difficult to address and has
remained controversial. Imatinib mesylate, a potent inhibitor of
PDGFR-b, has been found either to promote osteoblast
differentiation [36] or to suppress proliferation and alter
differentiation of human mesenchymal stromal cells, the osteoblast
precursors [37]. As mentioned above, the knockout of PDGFR-b
or PDGF-bb is lethal in mice. Therefore, more elaborated
strategies are needed to explore the functional importance of
PDGFR- b signaling in various tissues [28,29,24]. Very recently,
mutant mice in which PDGFR-b was depleted with the use of an
inducible Cre-loxP system were produced. The analysis of the
corresponding MSCs indicated that the depletion of PDGFR-b
enhances their osteogenic differentiation [38]. Our study shows
that preosteoblastic cells migrate more efficiently than mature
osteoblasts when stimulated by PDGF-bb, a phenomenon more
than likely explained by a down regulation of PDGFR-b during
osteoblastogenesis. Therefore, PDGF-bb/PDGFR-b signaling,
stimulating the migration of osteoblast progenitors and concom-
itantly inhibiting their differentiation, could provide an efficient
mechanism for a rapid mobilization of osteoblast precursors at
specific sites for efficient bone rebuilding and repair. To address
this point accurately, the conditional inactivation of PDGF-bb in
mouse osteoclasts and that of PDGFR-b in mouse osteoblast
precursors are certainly the next necessary steps to illustrate the
functional importance of PDGF-bb/PDGFR-b signaling in bone
remodeling and more generally the role of mature osteoclasts in
controlling bone rebuilding in vivo.
Materials and Methods
Cell culture and recombinant proteins
All cell lines were from ATCC (Rockville, MD, USA). Mouse
pre-osteoblastic MC3T3-E1 cells were maintained in a-MEM
supplemented with 10% heat inactivated Fetal Calf Serum (FCS).
Mouse myeloid Raw264.7 cells were cultured in high glucose
DMEM supplemented with 10% heat inactivated FCS. Primary
osteoclast precursors were obtained from bone marrow of long
bones of 8 week-old C57BL/6J mice. After purification on density
gradients (Eurobio), they were cultured in a-MEM supplemented
with 10% heat inactivated FCS. Soluble recombinant RANKL
was from Abcys (Paris, France) or produced in Pichia yeast as
described previously [39]. Recombinant human PDGF-bb was
from PeproTech EC (London, UK), human recombinant M-CSF
from Prospec Tany TechnoGene (Rehovot, Israel).
Differentiation of osteoblast and osteoclast precursors
MC3T3-E1 cells were differentiated into osteoblasts with
1027 M dexamethasone, 50 mg/ml ascorbic acid and 10 mM b-
glycerophosphate in a-MEM for <15 days. Raw264, 7 cells were
differentiated into multinucleated osteoclasts in the presence of
RANKL for 4–6 days as described [39]. Primary osteoclast
precursors isolated from bone marrow were differentiated in the
presence of M-CSF and RANKL [40]. The conditioned media of
osteoclasts were collected every 24 h, centrifuged, buffered with
20 mM HEPES pH 7, 2 and kept at 280uC until further use.
Chemotaxis Assay
Chemotactic responses were measured in triplicates using a 48-
well Boyden microchemotactic chamber [41]. The lower wells of the
apparatus were filled with growth factors in a-MEM containing
20 mM HEPES pH 7,2 or conditioned medium from Raw 264,7
cells or derived-osteoclasts and overlaid with a polycarbonate
membrane of 5 mm pores (NeuroProbe Inc. Gaithersburg MD,
USA). Cells (0.356105 MC3T3-E1, 0.456105 differentiated osteo-
blasts or 0.256105 7F2 cells) in 50 ml of a-MEM were added to the
upper wells. After a 3,5 h incubation at 37uC, the membrane was
removed. The cells on the upper surface were discarded by gentle
scraping and cells that had migrated to the other side of the
membrane were fixed with 3% Paraformaldehyde, stained with
toluidine blue (Sigma, Germany) and counted. The chemotactic
index (CI) represents the ratio between the average number of cells
migrating under given conditions and the average number of cells
migrating under control conditions.
Gene silencing in osteoclasts and osteoblasts
Raw 264,7 cells were differentiated into osteoclasts in the
presence of RANKL. After 2–3 days, they were detached by
incubation in PBS containing 0,5 mM EDTA. Pre-designed
stealth RNAi or scrambled stealth RNAi duplexes were electro-
porated into osteoclasts. Electroporated cells were resuspended in
medium supplemented with RANKL and maintained in culture
for 48 h. Conditioned media were collected and osteoclasts were
processed for total RNA isolation and protein determination.
Mouse preosteoblastic MC3T3-E1 cells or chemically differenti-
ated osteoblasts were transfected with Stealth siRNA duplex
oligonucleotides using Interferin as transfection reagent. After
48 h, the cells were harvested. The total RNAs were isolated.
Detailed information regarding stealth RNAi duplexes and
transfection methods is given in Materials and Methods S1
Quantitative RT-PCR Analyses
Total RNA was isolated. DNase I-treated RNAs were reverse
transcribed. Quantitative RT-PCR was performed with a
Stratagene Mx4000 QPCR system and the Brilliant SYBR Green
QPCR kit according to the manufacturer’s instructions (Strata-
gene, La Jolla, CA). Quantitative RT-PCR analyses were
performed in triplicates, and Ct values were normalized using
GAPDH. Primer sequences and detailed methods are given in
Materials and Methods S1.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0003537.s001 (0.05 MB
DOC)
Figure S1
Found at: doi:10.1371/journal.pone.0003537.s002 (8.69 MB
DOC)
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